Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 11/2023

Inhalt (36 Artikel)

Open Access Review

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

Natalia Sauer, Natalia Janicka, Wojciech Szlasa, Bartłomiej Skinderowicz, Katarzyna Kołodzińska, Wioletta Dwernicka, Małgorzata Oślizło, Julita Kulbacka, Vitalij Novickij, Katarzyna Karłowicz-Bodalska

Review

Cancer management during the COVID-19 world pandemic

Navid Sobhani, Giuseppina Mondani, Giandomenico Roviello, Martina Catalano, Marianna Sirico, Alberto D’Angelo, Bruna Scaggiante, Daniele Generali

Review

Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies

Tavus Atajanova, Md Mahfuzur Rahman, David J. Konieczkowski, Zachary S. Morris

Review

Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics

Peipei Li, Fangchao Li, Yanfei Zhang, Xiaoyang Yu, Jingjing Li

Research

BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy

Steven H. Sun, Colin D. Angell, Himanshu Savardekar, Debasish Sundi, David Abood, Brooke Benner, Mallory J. DiVincenzo, Megan Duggan, Fouad Choueiry, Thomas Mace, Prashant Trikha, Gabriella Lapurga, Courtney Johnson, Erick J. Carlson, Catherine Chung, Blake R. Peterson, Lianbo Yu, Jing Zhao, Kari L. Kendra, William E. Carson III

Open Access Research

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

C. Schmitt, E. P. Hoefsmit, T. Fangmeier, N. Kramer, C. Kabakci, J. Vera González, J. M. Versluis, A. Compter, T. Harrer, H. Mijočević, S. Schubert, T. Hundsberger, A. M. Menzies, R. A. Scolyer, G. V. Long, L. E. French, C. U. Blank, L. M. Heinzerling

Open Access Research

Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCII+ CD163− macrophages

Fany Blanc, Nicolas Bertho, Guillaume Piton, Jean-Jacques Leplat, Giorgia Egidy, Emmanuelle Bourneuf, Silvia Vincent-Naulleau, Armelle Prévost-Blondel

Research

Role of single-cell ferroptosis regulation in intercellular communication and skin cutaneous melanoma progression and immunotherapy

Binyu Song, Yixuan Peng, Yu Zheng, Yuhan Zhu, Wei Liu, Kai Wang, Zhiwei Cui, Baoqiang Song

Research

Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions

Koki Uehara, Kenro Tanoue, Kyoko Yamaguchi, Hirofumi Ohmura, Mamoru Ito, Yuzo Matsushita, Kenji Tsuchihashi, Shingo Tamura, Hozumi Shimokawa, Taichi Isobe, Yoshihiro Shibata, Hiroshi Ariyama, Risa Tanaka, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Koichi Akashi, Eishi Baba

Open Access Research

HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia

Hana Komic, Alexander Hallner, Brwa Ali Hussein, Chiara Badami, Anne Wöhr, Kristoffer Hellstrand, Elin Bernson, Fredrik B. Thorén

Research

A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer

Ayse Ece Gulen, Rakesh Rudraboina, Mohammad Tarique, Vahap Ulker, Haval Shirwan, Esma S. Yolcu

Open Access Research

Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study

Chikako Iwai, Taisuke Jo, Takaaki Konishi, Asahi Fujita, Nobuaki Michihata, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga

Research

Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer

Naomi Sugimura, Eiji Kubota, Yoshinori Mori, Mineyoshi Aoyama, Mamoru Tanaka, Takaya Shimura, Satoshi Tanida, Randal N. Johnston, Hiromi Kataoka

Open Access Research

Th1 cytokines in pediatric acute lymphoblastic leukemia

Sarah Schober, Jennifer M. Rottenberger, Johannes Hilz, Evi Schmid, Martin Ebinger, Tobias Feuchtinger, Rupert Handgretinger, Peter Lang, Manon Queudeville

Research

Intravenous injection of tumor extracellular vesicles suppresses tumor growth by reducing the regulatory T cell phenotype

Sanshiro Kobayashi, Naoyuki Kondo, Takashi Tomiyama, Naohiro Nakamura, Masataka Masuda, Yasushi Matsumoto, Yusuke Honzawa, Tomomitsu Tahara, Tsukasa Ikeura, Toshiro Fukui, Kazuichi Okazaki, Makoto Naganuma

Research

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Yohei Okada, Francesco Massari, Georgia Anguera Palacios, Michele Dionese, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin W. Myint, Luca Galli, Vinicius Carrera Souza, Renate Pichler, Ugo De Giorgi, María Natalia Gandur Quiroga, Danielle Gilbert, Lazar Popovic, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J. Crabb, Javier Molina-Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Küronya, Rita Chiari, Saul Campos, Orazio Caffo, André P. Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino Marques Monteiro, Breno Dauster, Carlo Cattrini, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luís Garcia Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernandez, Maria Bassanelli, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michele Milella, Jindrich Kopecky, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchenhorn, Daniele Santini, Ray Manneh, Renato Bisonni, Roubini Zakopoulou, Alessandra Mosca, Franco Morelli, Fernando Maluf, Andrey Soares, Fernando Nunes, Alvaro Pinto, Anca Zgura, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Nicola Battelli, Camillo Porta, Joaquim Bellmunt, Matteo Santoni

Open Access Research

Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis

Bijing Xiao, Hui Ouyang, Haimiti Gulizeba, Haiyan Fu, Zhiqiang Wang, Yan Huang

Research

Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer

Yakun Zhang, Yue Sun, Jing Gan, Hanxiao Zhou, Shuang Guo, Xinyue Wang, Caiyu Zhang, Wen Zheng, Xiaoxi Zhao, Yunpeng Zhang, Shangwei Ning, Xia Li

Open Access Research

Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study

Melissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, Alessandro Parisi, Marcello Tiseo, Paola Bordi, Maria Michiara, Simona Bui, Agnese Cosenza, Leonarda Ferri, Giulia Claire Giudice, Irene Testi, Elena Rapacchi, Roberta Camisa, Bruno Vincenzi, Giuseppe Caruso, Antonio Natale Rauti, Federica Arturi, Marco Tucci, Valentina Santo, Valentina Ricozzi, Vanessa Burtet, Paolo Sgargi, Renata Todeschini, Fable Zustovich, Luigia Stefania Stucci, Daniele Santini, Sebastiano Buti

Research

Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis

Jiashuo Chao, Shanshan Wang, Hao Wang, Nan Zhang, Yunchao Wang, Xu Yang, Chengpei Zhu, Cong Ning, Xinmu Zhang, Jingnan Xue, Longhao Zhang, Mingjian Piao, Mingming Wang, Xiaobo Yang, Ling Lu, Haitao Zhao

Research

Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment

Wei-Wei Zheng, Hang Zhou, Ping Li, Shi-Guang Ye, Tuersunayi Abudureheman, Li-Ting Yang, Kai Qing, Ai-Bin Liang, Kai-Ming Chen, Cai-Wen Duan

Open Access Research

Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer

Koji Teramoto, Tomoyuki Igarashi, Yoko Kataoka, Mitsuaki Ishida, Jun Hanaoka, Hidetoshi Sumimoto, Yataro Daigo

Open Access Research

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

Shinsuke Ogusu, Yuhei Harutani, Takehiro Tozuka, Ryota Saito, Junji Koyama, Hiroaki Sakamoto, Tomoaki Sonoda, Yuko Tsuchiya-Kawano, Tomohiro Oba, Keita Kudo, Hiroshi Gyotoku, Katsumi Nakatomi, Ryo Ariyasu

Research

Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1

Sung Soo Mun, Jeremy Meyerberg, Leila Peraro, Tatyana Korontsvit, Thomas Gardner, Manish Malviya, Chrisann Kyi, Roisin E. O’Cearbhaill, Cheng Liu, Tao Dao, David A. Scheinberg

Open Access Research

PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer

Kento Kawasaki, Kazuhiro Noma, Takuya Kato, Toshiaki Ohara, Shunsuke Tanabe, Yasushige Takeda, Hijiri Matsumoto, Seitaro Nishimura, Tomoyoshi Kunitomo, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Hajime Kashima, Naoaki Maeda, Satoru Kikuchi, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

Open Access Research

Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)

Emanuele Vita, Alessio Stefani, Geny Piro, Luca Mastrantoni, Marco Cintoni, Giuseppe Cicchetti, Ileana Sparagna, Federico Monaca, Guido Horn, Jacopo Russo, Diletta Barone, Mariantonietta Di Salvatore, Rocco Trisolini, Filippo Lococo, Ciro Mazzarella, Alessandra Cancellieri, Carmine Carbone, Anna Rita Larici, Maria Cristina Mele, Sara Pilotto, Michele Milella, Giampaolo Tortora, Emilio Bria

Open Access Research

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

A.-M. Arendt, F. Heubach, C. P. Maier, S. Giardino, G. Jung, E. Kowalewski, A. Rabsteyn, G. Amorelli, C. Seitz, P. Schlegel, R. Handgretinger, P. Lang

Open Access Research

GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model

Juan A. Hernández-Aceves, Jacquelynne Cervantes-Torres, Diana Torres-García, Francisco J. Zuñiga-Flores, Osiris J. Patiño-Chávez, Jorge A. Peña Agudelo, José Eduardo Aguayo-Flores, Yonathan Garfias, Laura Montero-León, Laura Romero-Romero, Armando Pérez-Torres, Gladis Fragoso, Edda Sciutto

Open Access Research

Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma

Lisa May Ling Tachiki, Daniel S. Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A. Goldstein, Joshua Veatch, Joel Ho, Paul T. Nghiem, John A. Thompson, Shailender Bhatia

Research Report

Radiation-induced dormancy of intracerebral melanoma: endotoxin inflammation leads to both shortened tumor dormancy and long-term survival with localized senescence

Sharif M. Ridwan, Rose Emlein, Asghar Mesbahi, Andrew Annabi, James F. Hainfeld, Henry M. Smilowitz

Open Access Brief Report

Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy

Julia Kleber, Jordi Yang Zhou, Florian Weber, Florian Bitterer, Patricia Hauer, Paul Kupke, Katharina Kronenberg, Edward K. Geissler, Hans J. Schlitt, Matthias Hornung, James A. Hutchinson, Jens M. Werner

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.